Table 4.
Multivariable Cox proportional hazard results for overall survival in single agent bevacizumab and lomustine monotherapy (BELOB) using continuous measures of ADCL.
| Treatment Arm | Variable | Coefficient | Hazard Ratio (95% C.I.) | P-Value |
|---|---|---|---|---|
| Bevacizumab Monotherapy | Age | −0.0037 ± 0.0167 | 0.9964 (0.9643 – 1.0294) | 0.8265 |
| Volume (Continuous) | 0.0440 ± 0.0131 | 1.0450 (1.0186 – 1.0721) | 0.0008*** | |
| ADCL (Continuous) | −2.5328 ± 1.1341 | 0.0764 (0.0086 – 0.7335) | 0.0255* | |
|
| ||||
| Lomustine Monotherapy | Age | 0.0108 ± 0.0227 | 1.0109 (0.9669 – 1.0569) | 0.6343 |
| Volume (Continuous) | 0.0360 ± 0.0123 | 1.0367 (1.0120 – 1.0620) | 0.0034** | |
| ADCL (Continuous) | −1.0349 ± 0.8965 | 0.3553 (0.0613 – 2.0591) | 0.2483 | |